布拉氏酵母菌联合柳氮磺吡啶肠溶片治疗UC的临床研究  

Clinical Study of Saccharomyces Boulardii Combined with Sulfasalazine Enteric-Coated Tablets in Treatment of Ulcerative Colitis

作　　者：李鸿儒 辛祎 冯鹏飞 王永辉 LI Hong-ru;XIN Yi;FENG Peng-fei;WANG Yong-hui(Department of Pharmacy,Zhumadian Central Hospital,Zhumadian,Henan 463000;Department of Pharmacy,First Affiliated Hospital of Henan University,Kaifeng,Henan 475001;Department of Gastroenterology,Zhumadian Central Hospital,Zhumadian,Henan 463000)

机构地区：[1]驻马店市中心医院药学部,河南驻马店463000 [2]河南大学第一附属医院药学部,河南开封475001 [3]驻马店市中心医院胃肠内科,河南驻马店463000

出　　处：《中国肛肠病杂志》2025年第2期44-46,共3页Chinese Journal of Coloproctology

基　　金：河南省高等学校重点科研项目(22A310002);河南省医学科技攻关计划项目(LHGJ20231008)。

摘　　要：目的:探讨布拉氏酵母菌联合柳氮磺吡啶肠溶片治疗溃疡性结肠炎(UC)的临床疗效及对肠黏膜屏障功能的影响。方法:将2023年2月至2024年2月我院收治的符合入组标准的80例UC患者随机分为观察组和对照组,各40例。对照组接受柳氮磺吡啶治疗,观察组接受柳氮磺吡啶+布拉氏酵母菌治疗。2组均治疗2个月。比较2组临床总体疗效、症状缓解时间,治疗前后Baron内镜评分、Sutherland疾病活动指数,以及治疗前后肠黏膜屏障功能指标血清内毒素(ET)、D-乳酸、二胺氧化酶(DAO)水平。结果:观察组治疗总有效率(95.00%)明显高于对照组(80.00%),腹泻、腹痛、黏液脓血便、发热症状缓解时间明显短于对照组,P<0.05。2组治疗后Baron内镜评分、Sutherland疾病活动指数及血清ET、D-乳酸、DAO水平均较治疗前降低,P<0.05;治疗后2组间比较,观察组Baron内镜评分、Sutherland疾病活动指数及血清ET、D-乳酸、DAO水平更低,P<0.05。结论:与单用柳氮磺吡啶肠溶片治疗UC相比,联合应用布拉氏酵母菌可促进UC患者症状缓解,提高肠黏膜屏障功能,提高治疗效果。Objective To investigate the clinical efficacy of Saccharomyces boulardii combined with Sulfasalazine enteric-coated tablets in the treatment of ulcerative colitis(UC)and its effect on intestinal mucosal barrier function.Methods A total of 8o UC patients who met the inclusion criteria and were admitted to our hospital from February 2023 to February 2024 were randomly divided into the observation group and the control group,40 cases in each group.The control group was treated with Sulfasalazine,and the observation group was treated with Sulfasalazine+Saccharomyces boulardi.Both groups were treated for 2 months.The overall clinical efficacy,symptom remission time,Baron endoscopic score and Sutherland disease activity index before and after treatment,and the intestinal mucosal barrier function indicators including serum levels of endotoxin(ET),D-lactic acid and diamine oxidase(DAO)before and after treatment were compared between the two groups.Results The total effective rate of the observation group(95.00%)was significantly higher than that of the control group(80.00%),and the remission time of diarrhea,abdominal pain,mucopurulent bloody stool,and fever in the observation group was significantly shorter than that in the control group(P<o.05).After treatment,the Baron endoscopy score,Sutherland disease activity index,and serum levels of ET,D-lactic acid and DAO were significantly lower than those before treatment in both groups(P<o.05).After treatment,the Baron endoscopy score,Sutherland disease activity index,and serum levels of ET,D-lactic acid,and DAO were significantly lower in the observation group than in the control group(P<0.05).C onclusion Compared with the simple use of Sulfasalazine enteric-coated tablets in the treatment of UC,the combined application of Saccharomyces boulardi can promote the relief of symptoms in UC patients,improve intestinal mucosal barrier function,and enhance the treatment effect.

关 键 词：溃疡性结肠炎 布拉氏酵母菌 柳氮磺吡啶 疗效 

分 类 号：R574.62[医药卫生—消化系统]